{"brief_title": "Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer", "brief_summary": "The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.", "condition": ["Carcinoma, Non-Small-Cell Lung"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["TLK286", "carboplatin", "paclitaxel"], "description": ["Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m\u00b2", "AUC 6 mg/mL/min Once every 3 weeks", "200 mg/m\u00b2 Once every 3 weeks"], "arm_group_label": ["Triplet Combination of TLK286 Carboplatin & Paclitaxel", "Triplet Combination of TLK286 Carboplatin & Paclitaxel", "Triplet Combination of TLK286 Carboplatin & Paclitaxel"], "criteria": "Inclusion Criteria: - 18 years of age or older - Histologically confirmed non-small cell lung cancer (NSCLC) - Stage IV or IIIB (disease that is not eligible for combined modality chemotherapy and radiation) - Measurable disease by RECIST - ECOG status of 0-1 - Adequate liver and renal function - Adequate bone marrow reserves Exclusion Criteria: - Prior chemotherapy, immunotherapy or biologic therapy for metastatic NSCLC - Up to one prior adjuvant or neoadjuvant chemotherapy is allowed - History of bone marrow transplantation or stem cell support - Pregnant or lactating women", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Non-small cell lung cancer", "mesh_term": ["Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Paclitaxel", "Albumin-Bound Paclitaxel", "Carboplatin"], "id": "NCT00088556"}